

Title	FOA number(s)	FOA sponsor (e.g. NICHD, FDA)	Application Deadline	Brief Description
<u>Genomic Centers for Infectious Diseases (U19 Clinical Trial Not Allowed)</u>	RFA-AI-18-004	National Institutes of Health, National Institute of Allergy and Infectious Diseases	22-Jun-2018	<p>The purpose of this initiative is to support Genomic Centers for Infectious Diseases (GCID) to promote broad use and expand the application of genomics technologies and computational analysis to understand infectious diseases, with an emphasis on pathogens, their interaction with the host and microbiome, and to aid in the development of novel genomics-based tools to diagnose, prevent and treat infectious diseases.</p>
<u>Newborn Screening New Condition Implementation: Capacity Building and Quality Improvement through Data Harmonization</u>	CDC-RFA-EH18-1804	Centers for Disease Control - NCEH	29-Jun-2018	<p>To increase the number of states and territories with fully implemented newborn screening programs.</p>

<p><u>Newborn Screening Family Education Program</u></p>	<p>HRSA-18-111</p>	<p>Health Resources and Services Administration</p>	<p>2-Jul-2018</p>	<p>The purpose of the cooperative agreement is to develop and deliver educational programs about newborn screening, counseling, testing, follow-up and treatment, specialty services and support activities that increase awareness, knowledge, and understanding of newborn screening for parents, families, patient advocacy and support groups</p>
<p><u>Malonic Aciduria – One (1)</u></p>		<p>NORD/ The Hope Fund</p>	<p>16-Jul-2018</p>	<p>The purpose of the NORD Research Grant Program is to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of rare “orphan” diseases.</p>

<u>Intermountain Precision Genomics Call for Research Proposals</u>		Intermountain Healthcare	1-Aug-2018	Collaborate with Intermountain Precision Genomics, leveraging Intermountain's access to samples as well as its high-throughput next-generation sequencing capabilities.
<u>Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01)</u>	RFA-FD-16-043	Food and Drug Administration	15-Oct-2018	The objective of FDA's Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics

<p><u>Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)</u></p>	<p>PAR-18-090</p>	<p>Health and Human Services-National Institutes of Health 11</p>	<p>7-May-2019</p>	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening.</p>
<p><u>Natural History of Disorders Identifiable by Screening of Newborns (R01)</u></p>	<p>PAR-16-061</p>	<p>Health and Human Services-National Institutes of Health 11</p>	<p>8-May-2019</p>	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening.</p>

<u>Ethical, Legal and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)</u>	PA-17-445	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research
<u>Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)</u>	PA-17-446	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.
<u>Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)</u>	RFA-HL-19-024	National Institutes of Health	6-May-2021	To support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in the mission areas of importance to NHLBI

<u>Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional)</u>	PAR-18-689	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
<u>Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional)</u>	PAR-18-690	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.

<u>Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional)</u>	PAR-18-691	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
<u>Content Development for the Newborn Screening Clearinghouse</u>		The Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB)	Ongoing	Develop and maintain a central clearinghouse of newborn screening information and provide expertise on newborn screening to inform this project.
<u>Child, Newborn, and Maternal Health Project</u>	RFA-391-13-000009	USAID-PAK	Ongoing	The purpose of this amendment is to cancel the Request for Application No.: 391-13-000009 implementation of the Child, Newborn, and Maternal Health Activity.